| Cas No.: | 1172118-03-4 |
| Chemical Name: | N-[6-[4-amino-1-[[8-methyl-2-(2-methylphenyl)-1-oxoisoquinolin-3-yl]methyl]pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzothiazol-2-yl]acetamide |
| Synonyms: | PI3Kγ inhibitor 1, AGN-PC-07162N, CHEMBL2216897, MolPort-027-836-537, AKOS016011504, AK120464, HY-10549 |
| SMILES: | O=C1N(C2=CC=CC=C2C)C(CN3N=C(C4=CC=C(N=C(NC(C)=O)S5)C5=C4)C6=C3N=CN=C6N)=CC7=CC=CC(C)=C71 |
| Formula: | C32H26N8O2S |
| M.Wt: | 586.666 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | The dual PI3Kg/d inhibitor INK055 was effective as prophylactic therapy as well as in established arthritis. The modest effect on autoantibody production and benefit observed in established disease suggests that the mechanism is through an effect on innate immunity rather than antibody production. A dual specific PI3Kg/d inhibitor might be effective in rheumatoid arthritis while limiting systemic toxicity of a and b inhibitors. For the detailed information of INK-055, the solubility of INK-055 in water, the solubility of INK-055 in DMSO, the solubility of INK-055 in PBS buffer, the animal experiment (test) of INK-055, the cell expriment (test) of INK-055, the in vivo, in vitro and clinical trial test of INK-055, the EC50, IC50,and affinity,of INK-055, Please contact DC Chemicals. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
